|
|
Volumn 25, Issue 19, 2007, Pages
|
|
Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
CONFLICT OF INTEREST;
CONSULTATION;
DRUG INDUSTRY;
ECONOMICS;
FORECASTING;
HUMAN;
INVESTMENT;
MEDICAL ETHICS;
NEOPLASM;
NOTE;
ONCOLOGY;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
COMMERCE;
CONFLICT OF INTEREST;
CONSULTANTS;
DRUG INDUSTRY;
ETHICS, PROFESSIONAL;
FORECASTING;
HUMANS;
INVESTMENTS;
MEDICAL ONCOLOGY;
NEOPLASMS;
|
|
EID: 34447551610
PISSN: None
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2007.11.1930 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
